NASDAQ: NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that has been focused on discovering and developing novel therapies to treat cancer. The company's pipeline includes SIM0505, an investigational antibody-drug conjugate (ADC) targeting CDH6 with a proprietary topoisomerase I inhibitor payload, and LNCB74, a B7-H4-directed ADC developed in collaboration with LigaChem Biosciences. NextCure has entered into a definitive merger agreement with Avere Therapeutics, a privately held biotechnology company developing oral therapies for IL-23-driven inflammatory diseases. The company is currently in a transitional phase, preserving capital and managing legacy assets ahead of the expected merger closing. Its retained clinical, regulatory, CMC, and finance personnel support the ongoing clinical development of LNCB74 under a transition agreement with LigaChem, manage patients enrolled in the SIM0505 study, and pursue efforts to partner, license, or monetize legacy clinical and preclinical assets. The company trades on Nasdaq under the ticker NXTC. Updated
Friday's top analyst upgrades and downgrades included Autodesk, Costco, Gap, Interactive Brokers, SBA Communications, Smith & Wesson, Western Digital and Zscaler.
NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As a result, NextCure shares were crushed on Monday.
Chris Lange NextCure appears to be one of those companies that has flown under the radar of the investing community since its initial public offering in 2019.
NextCure, Inc. is a clinical-stage biopharmaceutical company that has been focused on discovering and developing novel therapies to treat cancer.
